ISRCTN13632914已完成不适用
Phase III trial of the anti-angiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy
ederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) (The Netherlands)0 个研究点目标入组 216 人开始时间: 2006年12月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Good condition (Eastern Cooperative Oncology Group [ECOG] Performance Status [PS] zero to two)
- •2. First line therapy with pemetrexed minimum of four courses
- •3. A measurable lesion is not required
- •4. Normal laboratory values
- •5. Signed informed consent
- •6. Thalidomide therapy to start within nine weeks after last chemotherapy course
排除标准
- •1. Inaqdequate measures for birth control
- •2. Polyneuropathy more than grade one
- •3. Thrombo-embolic events
研究者
相似试验
已完成
3 期
MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy.ACTRN12609000141246niversity of Sydney14
已完成
不适用
S0230 Goserelina para prevenir la insuficiencia ovarica en mujeres que reciben quimioterapia para el cancer de mama-E288 Other ovarian dysfunctionOther ovarian dysfunctionE288PER-014-06EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
已完成
3 期
Phase III trial of the usefulness of new antidepilation conpound, DHL-HisZnNa, against the antineoplastic drug - induced depilation in breast cancer patientsbreast cancerJPRN-UMIN000014840Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine100
已完成
3 期
A randomised phase III study on the effect of thalidomide combined with Adriamycin®, dexamethasone and high dose melphalan in patients with multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsMultiple myelomaCancerISRCTN06413384Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)450
进行中（未招募）
1 期
A trial testing lenalidomide and dexamethasone after standard radiotherapy in patients with solitary bone plasmacytoma who are at a high risk of relapseEUCTR2015-001355-76-GBniversity College London140